@article{ref1,
title="The benefits and potential drawbacks in the approval of EVZIO for lay reversal of opioid overdose",
journal="American journal of preventive medicine",
year="2015",
author="Beletsky, Leo",
volume="48",
number="3",
pages="357-359",
abstract="In July 2014, Kaleo Pharmaceuticals launched its new product, EVZIO(tm) -- a naloxone hydrochloride - device combination -- for the emergency treatment of opioid overdose. Similar to an automated external defibrillator, the device is programmed to guide an untrained lay user through the provess of overdose reversal using prerecorded audiovisual prompts. It then deploys an EpiPen-like retractable mechanism to inject the opioid antagonist....<p /> <p>Language: en</p>",
language="en",
issn="0749-3797",
doi="10.1016/j.amepre.2014.09.011",
url="http://dx.doi.org/10.1016/j.amepre.2014.09.011"
}